tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Robyn Karnauskas, 366 are a BUY (83.56%), 69 are a HOLD (15.75%), 3 are a SELL (0.68%).
Analyst Robyn Karnauskas, currently employed at TRUIST, carries an average stock price target met ratio of 49.38% that have a potential upside of 43.43% achieved within 385 days.
Robyn Karnauskas’s has documented 888 price targets and ratings displayed on 51 stocks. The coverage is on Healthcare, Technology, Energy sectors.
Most recent stock forecast was given on LLY, Eli Lilly and Company at 19-Nov-2025.
Analyst best performing recommendations are on FATE (FATE THERAPEUTICS).
The best stock recommendation documented was for FATE (FATE THERAPEUTICS) at 1/5/2023. The price target of $7 was fulfilled within 1 day with a profit of $4 (36.36%) receiving and performance score of 363.64.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 25-Feb-2026
$260
$50.6 (24.16%)
$220
1 months 3 days ago
(25-Feb-2026)
5/6 (83.33%)
$33.08 (14.58%)
168
Buy Since 12-Sep-2025
$299
$89.6 (42.79%)
$284
1 months 10 days ago
(18-Feb-2026)
2/4 (50%)
$70.28 (30.73%)
35
Hold Since 07-Jan-2026
$230
$20.6 (9.84%)
$240
1 months 23 days ago
(05-Feb-2026)
1/2 (50%)
$10.98 (5.01%)
8
Buy Since 24-Jan-2022
$270
$60.6 (28.94%)
$269
1 months 23 days ago
(05-Feb-2026)
17/21 (80.95%)
$50.98 (23.28%)
526
Hold Since 14-May-2025
$230
$20.6 (9.84%)
$235
2 months 1 days ago
(27-Jan-2026)
19/20 (95%)
$6.07 (2.71%)
273
Which stock is Robyn Karnauskas is most bullish on?
What Year was the first public recommendation made by Robyn Karnauskas?
